Targeting IL-15 in large granular lymphocyte leukemia.

IL-15 is a cytokine that stimulates the proliferation of NK and T cells. Previous studies have shown that IL-15 is critical to the induction of T-cell large granular lymphocyte (T-LGL) leukemia. A Phase I trial of a humanized antibody (Hu-Mikß1) to the IL2/IL15Rß receptor, expressed on T-LGL, is explored in this trial to evaluate the safety, pharmacokinetics, specificity and clinical efficacy of Hu-Mikß1. The study demonstrated no toxicity and favorable saturation of IL2/IL15Rß receptor, but no clinical efficacy in this Phase I study. [ABSTRACT FROM AUTHOR]